Erythropoietin (epo) Or Derivative Patents (Class 514/7.7)
-
Publication number: 20120129770Abstract: Disclosed herein is an isolated polynucleotide molecule encoding protein such as erythropoietin or structural variants, comprising an expression regulating nucleotide sequence operatively linked to a nucleotide sequence(s) encoding said proteins. The said expression regulatory region comprises of Exon A and at least proximal region of Intron A of Major Immediate Early Region of human Cytomegalovirus or its functional variants which when transfected into host cells results in many fold increase in expression of the protein.Type: ApplicationFiled: June 22, 2010Publication date: May 24, 2012Inventors: Rajyashri Karur Ramakrishna, Ashok Kumar, Annapoorni Jegatheesan, Jonnala Ujwal Kumar, Veeresh Sangappa Hugar
-
Publication number: 20120128767Abstract: The present invention provides novel calcium phosphate nanoparticles suitable for efficient encapsulation of biologically active molecules. The invention further provides pharmaceutical compositions comprising these nanoparticles, as well as methods of making such nanoparticles and using them as carriers for therapeutic delivery of biologically active macromolecules.Type: ApplicationFiled: May 1, 2009Publication date: May 24, 2012Inventors: William W. LEE, Feng LU
-
Publication number: 20120128654Abstract: Methods for inhibiting the progression of neurodegenerative diseases and treating neurotrauma-induced damage and cerebrovascular disease are provided herein, the methods including the administration of a safe and effective amount of allantoin to a patient in need thereof. Also provided are pharmaceutical compositions including allantoin for the inhibition of the progression of neurodegenerative diseases and for the treatment of neurotrauma-induced damage and cerebrovascular disease.Type: ApplicationFiled: April 23, 2010Publication date: May 24, 2012Applicant: UNIVERSITY OF CINCINNATIInventors: Brian T. Terpstra, Caryl E. Sortwell
-
Patent number: 8183205Abstract: A therapeutic agent for ovulation disorder of the present invention is characterized in comprising Granulocyte colony-stimulating factor; and that the ovulation disorder is caused by Luteinized Unruptured Follicle.Type: GrantFiled: November 9, 2009Date of Patent: May 22, 2012Assignee: Satoru MAKINODAInventor: Satoru Makinoda
-
Publication number: 20120121701Abstract: The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject.Type: ApplicationFiled: December 13, 2011Publication date: May 17, 2012Inventors: Hsing-Wen Sung, Kiran Sonaje, Hosheng Tu
-
Publication number: 20120114633Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.Type: ApplicationFiled: April 6, 2010Publication date: May 10, 2012Inventors: Donald T. Moir, Daniel Aiello, Norton P. Peet, John D. Williams
-
Publication number: 20120114742Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L. MARTINEZ, Merry R. Sherman, Mark G.P. Saifer, L. David Williams
-
Publication number: 20120107408Abstract: Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins and phospholipids, distributed in the matrix, and a three-phase emulsion process for their preparation.Type: ApplicationFiled: January 11, 2012Publication date: May 3, 2012Inventors: Michael Ausborn, Olivier Lambert, Oskar Nagele
-
Patent number: 8168589Abstract: Method for treatment and/or prophylaxis of schizophrenia and related psychoses of a human being, erythropoietin being administered to the human being.Type: GrantFiled: August 24, 2007Date of Patent: May 1, 2012Inventor: Hannelore Ehrenreich
-
Publication number: 20120100103Abstract: Disclosed are in situ-forming injectable hydrogel and medical uses thereof. In the in situ-forming injectable hydrogel two or more homogeneous or heterogeneous polymers are bonded to each other by a dehydrogenation reaction between phenol or aniline moieties on adjacent polymers, wherein a polymer backbone is grafted with a phenol or aniline moiety using a linker. In contrast to conventional hydrogel, the in situ-forming injectable hydrogel is superior in terms of in vivo stability and mechanical strength thanks to the introduction of a water-soluble polymer as a linker which leads to an improvement in the reactivity of phenol or aniline moieties. Having the advantage of superior bio stability and mechanical strength, the hydrogel finds a variety of applications in the biomedical field.Type: ApplicationFiled: July 1, 2010Publication date: April 26, 2012Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park
-
Publication number: 20120100100Abstract: The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or that are at risk of exposure to DNA damage.Type: ApplicationFiled: May 13, 2010Publication date: April 26, 2012Inventors: Norman E. Sharpless, Patrick J. Roberts, Kwok Wong, Yan Liu, Soren Johnson
-
Publication number: 20120100229Abstract: The present invention includes a method of treating or preventing a CNS white matter injury in a patient in need thereof. The invention also includes a method of stimulating proliferation of a CNS cell in a patient in need thereof.Type: ApplicationFiled: March 25, 2010Publication date: April 26, 2012Inventor: Scott Rivkees
-
Publication number: 20120094906Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.Type: ApplicationFiled: May 29, 2009Publication date: April 19, 2012Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
-
Patent number: 8143220Abstract: Effective dosing regimens for neural stem cell proliferating and differentiating agents, kits comprising effective dosing regimens for neural stem cell proliferating and differentiating agents, and uses thereof are provided herein. Such kits and methods can be utilized acutely or chronically to treat a neurodegenerative disease or condition. Furthermore, the compositions and methods can be used continuously or intermittently in various dosing regimens.Type: GrantFiled: March 16, 2007Date of Patent: March 27, 2012Assignee: Stem Cell Therapeutics Corp.Inventors: Samuel Weiss, Christopher Gregg
-
Patent number: 8142781Abstract: The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the agents are therapeutic, diagnostic, or research agents.Type: GrantFiled: October 7, 2005Date of Patent: March 27, 2012Assignee: ArmaGen Technologies, Inc.Inventors: William M. Pardridge, Ruben J. Boado
-
Publication number: 20120071404Abstract: The present invention provides for a method for stimulating the proliferation of pluripotential stem cells in a mammal comprising administration of pregnancy related compounds more particularly human chorionic gonadotropin, leutenizing hormone or prolactin. The present invention further provides for a method of treatment of tissues or organs experiencing cellular damage, injury or disease.Type: ApplicationFiled: June 27, 2011Publication date: March 22, 2012Applicant: STEM CELL THERAPEUTICS CORP.Inventor: Joseph Tucker
-
Publication number: 20120064029Abstract: Compositions for treating nervous system conditions. In at least one embodiment of a stem cell conditioned medium of the present disclosure, the stem cell comprises a cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult, the cell culture supernatant produced by culturing at least one mammalian adipose stem cell to produce the at least one factor.Type: ApplicationFiled: September 19, 2011Publication date: March 15, 2012Inventors: Brian H. Johnstone, Keith Leonard March, Yansheng Du
-
Publication number: 20120064079Abstract: The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (Epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of Epo treatment. The invention provides a method of treating anemia in a mammal involving: administering erythropoietin (Epo) to the mammal; and administering to the mammal an agent selected from a soluble Epo-binding protein (Epo-bp), a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor, and a combination thereof. The invention also provides a method of reducing hypertension in a mammal receiving Epo, and pharmaceutical compositions containing a soluble Epo-bp and/or a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor.Type: ApplicationFiled: March 10, 2011Publication date: March 15, 2012Inventors: Jong Y. Lee, Mary S. Lee, John S. Lee
-
Publication number: 20120064062Abstract: Organic compounds showing the ability to inhibit bacterial omptin proteases, specifically Yersinia pestis plasminogen activator (Pla) are disclosed. The disclosed Y. pestis plasminogen activator inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by Y. pestis.Type: ApplicationFiled: September 13, 2011Publication date: March 15, 2012Inventors: Jon D. Goguen, Daniel Aiello, Donald T. Moir, Bing Li
-
Publication number: 20120064036Abstract: The embodiments provide methods of administering a high dose or a loading dose of a TPO modulator to a subject. The embodiments further provide methods of treating thrombocytopenia and/or neutropenia in a subject. Additionally, the embodiments further provide methods of increasing platelet production and/or enhancing the number of peripheral blood stem cells in a subject.Type: ApplicationFiled: May 27, 2010Publication date: March 15, 2012Inventors: Connie L. Erickson-Miller, Julian Jenkins
-
Patent number: 8133860Abstract: The present invention relates generally to the use of erythropoietin (EPO) to facilitate resuscitation from cardiac arrest. For a mammalian subject suffering from cardiac arrest, concurrent administration of EPO with resuscitation after the onset of ventricular fibrillation facilitates the resuscitation. Administration of EPO serves to attenuate myocardial abnormalities caused by cardiac arrest and the resuscitation efforts and favor improved resuscitation outcomes.Type: GrantFiled: July 20, 2006Date of Patent: March 13, 2012Assignee: Rosalind Franklin University of Medicine and ScienceInventor: Raúl J. Gazmuri
-
Patent number: 8128906Abstract: Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.Type: GrantFiled: August 11, 2010Date of Patent: March 6, 2012Assignee: Lyotropic Therapeutics, Inc.Inventor: David Anderson
-
Patent number: 8128905Abstract: Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.Type: GrantFiled: August 11, 2010Date of Patent: March 6, 2012Assignee: Lyotropic Therapeutics, Inc.Inventor: David Anderson
-
Publication number: 20120052067Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.Type: ApplicationFiled: July 22, 2011Publication date: March 1, 2012Applicant: Acceleron Pharma Inc.Inventor: Matthew L. Sherman
-
Patent number: 8124095Abstract: The invention provides compositions, methods, and kits for increasing transport of a neurotrophin (e.g., erythropoietin (EPO)) across the blood brain barrier while allowing its activity to remain substantially intact. The neurotrophin (e.g., EPO) is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.Type: GrantFiled: January 15, 2010Date of Patent: February 28, 2012Assignee: ArmaGen Technologies, Inc.Inventors: William M. Pardridge, Ruben J. Boado
-
Publication number: 20120045487Abstract: A multiphasic microfiber for a three-dimensional tissue scaffold and/or cellular support is provided in one aspect that includes at least one biocompatible material. The multiphasic microfiber optionally has a first phase and at least one distinct additional phase and is formed by electrohydrodynamic jetting. Further, such microfibers optionally have one or more biofunctional agents, which may be surface-bound moieties provided in spatial patterns. Multiphasic microfibers formed in accordance with the disclosure may form, in some cases, three-dimensional fiber scaffolds with precisely engineered, micrometer-scaled patterns for cellular contact guidance, which may thus support and/or promote cellular growth, proliferation, differentiation, repair, and/or regeneration for tissue and bioengineering applications.Type: ApplicationFiled: April 29, 2010Publication date: February 23, 2012Applicant: The Regents of the University of MichiganInventors: Joerg Lahann, Srijanani Bhaskar, Suparna Mandal
-
Publication number: 20120046226Abstract: The invention concerns a novel treatment multiple sclerosis, based on induced anaemia, followed by administration of an erythropoiesis-stimulating agent (ESA). In a preferred embodiment, the ESA is darbopoietin alpha, CERA or Hematide. The anaemia is induced by successive bloodlettings or by administration of an iron chelator, such as deferiprone, deferoxamine, polyanionic amines, substituted polyaza compounds, desferrithiocon, hydroxybenzyl-ethylenediamine-diacetic acid and pyridoxal isonicotinoyl hydra z one.Type: ApplicationFiled: February 12, 2010Publication date: February 23, 2012Applicant: Assis-tance Publique - Hopitaux de ParisInventors: Alain Creange, Frédéric Galacteros, Jean-Pascal Lefaucheur
-
Patent number: 8119595Abstract: The present invention provides an aqueous formulation of human erythropoietin having the storage stability over a long period without serum albumin, in which the formulation comprises a pharmaceutically effective amount of human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers; isotonic reagent; and buffering reagent.Type: GrantFiled: June 7, 2004Date of Patent: February 21, 2012Assignee: LG Life Sciences, Ltd.Inventors: Kyu Chan Kwon, Suk Young Choi, Young Cheol Kang, Hoon Sung Jeh, Seung Joo Lee, Myung Jin Kim, Ji Eon Kim, Jin-Seok Oh
-
Publication number: 20120039805Abstract: The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial; lymphomas, sarcomas, melanomas, and the like, comprising determining the level of caveolin-1 and/or caveolin-2 in stromal cells adjacent to a neoplasm.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventors: Michael P. Lisanti, Federica Sotgia, Richard G. Pestell
-
Patent number: 8114839Abstract: Modified erythropoietin polypeptides that include the mutation R131Q, and uses thereof are provided. Also provided are pharmaceutical compositions, including compositions formulated for oral administration, that contain the modified erythropoietin polypeptides and uses of the compositions to treat diseases and conditions treated by erythropoietin.Type: GrantFiled: June 6, 2008Date of Patent: February 14, 2012Assignee: HanAll BioPharma Co., Ltd.Inventors: Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon
-
Patent number: 8106154Abstract: Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis.Type: GrantFiled: January 30, 2008Date of Patent: January 31, 2012Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Anjan Chakrabarti, Brian T. Frederick, Yijun Pan, Yaohua S. Dong, Ashok Bhandari
-
Publication number: 20120020974Abstract: The methods described herein can be used to identify ex ante which hemodialysis patients are likely to develop EPO resistance and therefore will require additional rHu EPO, and to provide treatments that can reduce the need for additional rHu EPO. In addition, the methods can be used to predict which subjects have a higher risk of mortality, to identify high-risk patients who can then be monitored more closely or treated more aggressively. Also provided are kits for carrying out the described methods.Type: ApplicationFiled: October 16, 2009Publication date: January 26, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE GENERAL HOSPITAL CORPORATIONInventors: Ravi Thadhani, S. Ananth Karumanchi, Eliyahu Khankin, Walter P. Mutter
-
Publication number: 20120020915Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.Type: ApplicationFiled: January 13, 2011Publication date: January 26, 2012Applicants: QUEENS UNIVERSITY AT KINGSTON, THE SIR MORTIMER B. DAVIS JEWISH GENERAL HOSPITAL, OSTA BIOTECHNOLOGIES, INC.Inventors: Ajay Gupta, Hyman M. Schipper, Moulay Alaoui-Jamali, Walter A. Szarek, Kanji Nakatsu, Jason Z. Vlahakis
-
USE OF TUMOR NECROSIS FACTOR-alpha RECEPTOR p75 FOR TREATMENT OF ISCHEMIA-INDUCED NEOVASCULARIZATION
Publication number: 20120014879Abstract: Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients.Type: ApplicationFiled: October 24, 2006Publication date: January 19, 2012Applicant: CARITAS ST. ELIZABETH MEDICAL CENTER OF BOSTON INCInventors: Douglas W. Losordo, David A. Goukassian -
Patent number: 8084424Abstract: Disclosed are methods and compositions related to the production of erythropoietin. The disclosed compositions comprise a poly amino acid. The production of erythropoietin by the disclosed compositions and methods can take place in vivo, in which the proliferation of a subject's erythropoietin-producing cells leads to an increased level of production of erythropoietin, in vitro, in which increased proliferation of cultured erythropoietin-producing cells leads to an increased production of erythropoietin, ex vivo, in which cells or tissues harvested from a subject produce erythropoietin. The disclosed compositions can be administered to a subject or applied to cells or tissues to stimulate increased production of erythropoietin.Type: GrantFiled: April 9, 2004Date of Patent: December 27, 2011Assignee: University of Utah Research FoundationInventors: Bellamkonda Kishore, Christof Westenfelder, Jorge Issac
-
Publication number: 20110311473Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: ApplicationFiled: June 21, 2011Publication date: December 22, 2011Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: HUNTINGTON POTTER, Gary W. Arendash, Steven Bennett, Timothy Boyd
-
Publication number: 20110311478Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.Type: ApplicationFiled: August 19, 2011Publication date: December 22, 2011Inventor: Joe Ernest BROWN
-
Publication number: 20110311477Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anaerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.Type: ApplicationFiled: August 19, 2011Publication date: December 22, 2011Inventor: Joe Ernest Brown
-
Publication number: 20110305776Abstract: The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).Type: ApplicationFiled: November 11, 2009Publication date: December 15, 2011Applicant: FibroGen, Inc.Inventors: Wen-Bin Ho, Lee A. Flippin, Craig Mossman, Eric D. Turtle, Lee R. Wright
-
Patent number: 8071543Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.Type: GrantFiled: October 31, 2007Date of Patent: December 6, 2011Assignee: Sygnis Bioscience GmbH & Co. KGInventors: Wolf-Ruediger Schaebitz, Armin Schneider, Carola Krueger, Clemens Sommer, Stefan Schwab, Rainer Kollmar, Martin Maurer, Daniela Weber, Nikolaus Gassler
-
Publication number: 20110294732Abstract: The present invention provides methods and compositions to replace up to 90% of erythropoietin use in the treatment of anemias and hypoxias. The method employs acid and salt forms of inositol-tripyrophosphate (ITPP) isomers to shift the P50 value of hemoglobin, thereby improving the rate and efficiency of oxygenation by blood even when red blood cell counts are low. Indications for the new method include anemias and hypoxia arising from infection, chemotherapy, premature birth, altitude change, compromised lung or heart function, aplastic anemia and anemia associated with a myelodysplastic syndrome, and other causes.Type: ApplicationFiled: July 5, 2011Publication date: December 1, 2011Applicants: Universite De Strasbourg, Normoxys, Inc.Inventors: Claude NICOLAU, Jean-Marie Lehn, Ruth Greferath
-
Patent number: 8067365Abstract: The compositions and methods disclosed herein are for prevention or treatment of multi-organ failure with erythropoietin. The usefulness of the present invention is that erythropoietin may act to prevent the onset of MOF in a patient at risk of developing it. The present invention may further lessen the effect in one or more affected organs in a patient at risk of developing MOF or in one already diagnosed with it.Type: GrantFiled: November 22, 2005Date of Patent: November 29, 2011Assignee: University of Utah Research FoundationInventor: Christof Westenfelder
-
Patent number: 8067366Abstract: The present invention relates generally to the use of erythropoietin (EPO) to facilitate resuscitation from cardiac arrest. For a mammalian subject suffering from cardiac arrest, concurrent administration of EPO with resuscitation after the onset of ventricular fibrillation facilitates the resuscitation. Administration of EPO serves to attenuate myocardial abnormalities caused by cardiac arrest and the resuscitation efforts and favor improved resuscitation outcomes. The main effect of EPO that facilitates resuscitation is the preservation of left ventricular myocardial distensibility leading to improve left ventricular preload and the amount of blood ejected by chest compression. This effect enables higher coronary perfusion pressures to be generated resulting in a higher rate of return of spontaneous circulation and higher survival rates. The very same effect enables the return of spontaneous circulation to occur faster reducing the time a human subject is in cardiac arrest.Type: GrantFiled: November 6, 2009Date of Patent: November 29, 2011Assignee: Rosalind Frankling University of Medicine and ScienceInventor: Raul J. Gazmuri
-
Publication number: 20110275564Abstract: This disclosure relates to erythropoietin (EPO) fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.Type: ApplicationFiled: August 4, 2008Publication date: November 10, 2011Applicant: ASTERION LIMITEDInventors: Peter Artymiuk, Richard Ross, Jon Sayers
-
Patent number: 8053407Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.Type: GrantFiled: October 31, 2007Date of Patent: November 8, 2011Assignee: Sygnis Bioscience GmbH & Co. KGInventors: Wolf-Ruediger Schaebitz, Armin Schneider, Carola Krueger, Clemens Sommer, Stefan Schwab, Rainer Kollmar, Martin Maurer, Daniela Weber, Nikolaus Gassler
-
Publication number: 20110269681Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.Type: ApplicationFiled: December 29, 2010Publication date: November 3, 2011Applicant: STEM CELL THERAPEUTICS INC.Inventors: Tetsuro Shingo, Samuel Weiss
-
Publication number: 20110262525Abstract: This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.Type: ApplicationFiled: December 11, 2007Publication date: October 27, 2011Applicant: SCHERING CORPORATIONInventors: Yan Wang, Chen Zong, Cynthia Seidel-Dugan, Yaolin Wang, Siu-Long Yao, Brian Der-Hua Lu, Mohamad H. Ladha
-
Publication number: 20110250169Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: ApplicationFiled: May 13, 2011Publication date: October 13, 2011Inventor: George N. Cox, III
-
Publication number: 20110250243Abstract: Poly(ethylene carbonate) (PEC) nanoparticles comprising pharmacologically active substances, their production method and their use for sustained release of the pharmacologically active agent after application are described.Type: ApplicationFiled: December 14, 2009Publication date: October 13, 2011Inventors: Thomas Kissel, Holger Petersen
-
Publication number: 20110250167Abstract: The present invention provides methods and kits for purifying a target protein group. The method comprises the steps of contacting a sample comprising at least 95% of the target protein group and at most 5% of contaminating proteins with a library of binding moieties having different binding moieties, binding the contaminating proteins and a minority of the target protein group to the library of binding moieties, separating the unbound target protein group from the proteins bound to the library of binding moieties and collecting the unbound target protein. The collected target protein is more pure than the target protein group in the sample.Type: ApplicationFiled: June 24, 2010Publication date: October 13, 2011Applicant: BIO-RAD LABORATORIES, INC.Inventors: Egisto Boschetti, Lee O. Lomas